kabutan

ASKA Pharma, 8% Increase in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 5 Yen, This Fiscal Year to Increase Dividend by 5 Yen

Mon May 11, 2026 3:30 pm JST Earnings

4886 ASKA Pharmaceutical Holdings Co.,Ltd. 【J-GAAP】

Earnings Report

ASKA Pharmaceutical Holdings Co.,Ltd. <4886> [TSE Prime] announced its financial results after the market closed on May 11th (15:30). The consolidated ordinary profit for the fiscal year ended March 2026 increased by 10.9% from the previous period to 5.66 billion yen. For the fiscal year ending March 2027, the consolidated ordinary profit is expected to grow by 7.7% to 6.10 billion yen. This will be the eighth consecutive term of revenue growth.

At the same time, the company increased the annual dividend for the previous term from 55 yen to 60 yen (compared to 55 yen in the prior term), and has decided to increase the dividend this fiscal year to 65 yen, an increase of 5 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit/loss turned to a profit of 0.81 billion yen (compared to a loss of 0.33 billion yen in the same period last year). The operating profit/loss margin drastically improved from -1.2% in the same period last year to 5.5%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
Mar, 2026 71,127 5,834 5,665 5,424 191.1 60 May 11, 2026 J-GAAP
YoY +10.9% +9.4% +10.9% +6.3% +6.2%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Guidance 71,000 6,000 6,000 5,000 176.1 55 Nov 4, 2025 J-GAAP
Mar, 2026 Results 71,127 5,834 5,665 5,424 191.1 60 May 11, 2026 J-GAAP
Revision Rate +0.2% -2.8% -5.6% +8.5% +8.5%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 35,253 2,649 2,660 2,226 78.5 27 Nov 4, 2025 J-GAAP
Apr - Sep, 2026 Guidance ー ー ー ー － 32 May 11, 2026 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
Mar, 2026 71,127 5,834 5,665 5,424 191.1 60 May 11, 2026 J-GAAP
Mar, 2027 Guidance 73,000 6,200 6,100 4,800 169.0 65 May 11, 2026 J-GAAP
YoY +2.6% +6.3% +7.7% -11.5% -11.6%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2025 14,213 -164 -339 1,003 35.4 -1.2 May 12, 2025 J-GAAP
Apr - Jun, 2025 17,641 1,479 1,620 1,244 43.9 8.4 Aug 4, 2025 J-GAAP
Jul - Sep, 2025 17,612 1,170 1,040 982 34.6 6.6 Nov 4, 2025 J-GAAP
Oct - Dec, 2025 19,233 2,262 2,194 1,678 59.1 11.8 Feb 2, 2026 J-GAAP
Jan - Mar, 2026 16,641 923 811 1,520 53.6 5.5 May 11, 2026 J-GAAP
YoY +17.1% － － +51.5% +51.4%

Related Articles